Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks .

Recent Articles

AMC Is Worth a Good Deal More at $58, Present Losses or Not

By Mark R. Hake, CFA Sep 2, 2021

AMC stock is still worth more, despite its present losses. AMC is worth some 32% more because it could eventually make positive FCF.

Oracle Remains a Free Cash Flow Powerhouse

By Mark R. Hake, CFA Sep 2, 2021

Oracle remains a free cash flow powerhouse. Its FCF this year could lead to a minimum expected return for ORCL stock of about 15%.

Powerful Free Cash Flow Could Push Amazon Over $4,000 Per Share

By Mark R. Hake, CFA Sep 2, 2021

Amazon's powerful FCF could push AMZN stock higher. It is worth $4,012 per share based on its average FCF margins and sales estimates for 2022.

FuboTV Is Set to Climb Higher as Its Subscribers and Revenue Grow

By Mark R. Hake, CFA Sep 1, 2021

FuboTV is set to move higher as subscribers and ARPU grow. As revenue and FCF climb, FUBO stock is likely to rise over 45% in the next year.

Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved

By Mark R. Hake, CFA Sep 1, 2021

Ocugen still hopes its Covid-19 vaccine gets approved to start making revenue. OCGN-stock could be worth as much as $9.09 or 19% over today's price assuming its Covid-19 vaccine gets approval.